The present disclosure is directed to a urinary catheter product. More particularly, the present disclosure is directed to a urinary catheter product with an indicator. Even more particularly, the present disclosure is directed to a urinary catheter product with a biomarker strip within the lumen of the catheter configured to identify characteristics of a user's urine.
Intermittent catheterization is a good option for many users who suffer from various abnormalities of the urinary system. With the advent of intermittent urinary catheters, individuals with problems associated with the urinary system can conveniently self-catheterize to drain the individual's bladder. Individuals who suffer from urinary incontinence will self-catheterize several times a day.
Although catheters are typically prepared in sterile environments and are provided with safe handling instructions, catheter users are at risk of contracting a urinary tract infection due to several different factors. For example, the catheters may become contaminated during use and introduce bacteria into the urethra. The catheter also may carry bacteria along the urinary tract.
Urinary tract infections pose significant health risks to the user and are often not detected early enough before symptoms develop. Symptoms of urinary tract infections may include abdominal pain, back pain, pain with catheterization, and fever. One way to prevent urinary tract infections is by having a urodynamic evaluation done by a doctor. Such evaluations may be awkward for the individual and unrealistic for users that catheterize multiple times a day.
Therefore, there is a need for methods and devices that allow urinary catheter users to obtain information about the characteristics of the user's urine and alerting them as early as possible of a potential for a urinary tract infection.
There are several aspects of the present subject matter which may be embodied separately or together in the devices claimed below. These aspects may be employed alone or in combination with other aspects of the subject matter described herein, and the description of these aspects together is not intended to preclude the use of these aspects separately or the claiming of such aspects separately or in different combinations as set forth in the claims appended hereto.
In one aspect, a urinary catheter product is provided. The urinary catheter product includes a catheter tube having a proximal insertion end and a distal drainage end. The urinary catheter product also includes a lumen extending from the proximal insertion end to the distal drainage end. The proximal insertion end has an opening for receiving urine in communication with the lumen and the distal drainage end has a drainage opening for draining urine from the lumen. Additionally, the urinary catheter product includes a biomarker strip within the lumen of the catheter product.
A more detailed description of the device in accordance with the present disclosure is set forth below. It should be understood that the description of the specific devices below is intended to be exemplary, and not exhaustive of all possible variations or applications. Thus, the scope of the disclosure is not intended to be limiting and should be understood to encompass variations or embodiments that would occur to persons of ordinary skill.
Furthermore, the distal drainage end 16 of the catheter tube 12 includes a drainage opening 20 for draining urine from the lumen. In one embodiment, the distal drainage end 16 includes a drainage member 24, further defining the lumen of the catheter 10. The drainage member 24 may be, for example, but not limited to, a funnel or connector for connection to a drainage bag (not shown). Other drainage members known in the art may be used without departing from the scope of the present disclosure.
A biomarker strip 22 containing at least one indicator 26 may be inserted inside the lumen of the catheter product 10 near the distal drainage end 16 of the catheter product 10. The biomarker strip includes a front surface 23 and a rear surface 25. The biomarker strip 22 contains multiple indicators 26 (
In one embodiment, the biomarker strip 22 is embedded in the distal drainage end 16 of the catheter product 10. The biomarker strip 22 may be secured to an inside surface of the catheter tube 12 inside the lumen of the catheter product 10 in a suitable manner. For example, but not limited to, the biomarker strip 22 may be secured to the inside surface of the catheter tube 12 by adhesives, mechanical fit, sonic welding, embedding, or other methods known to a person skilled in the art.
In another embodiment, the biomarker strip 22 may be embedded in, attached, or otherwise affixed to the drainage member 24. The biomarker strip 22 may be secured to the drainage member 24, for example, but not limited to, by adhesives, mechanical fit, sonic welding, embedding, or other methods known to a person skilled in the art.
Turning to
The biomarker strip 22 contacts a user's urine during voiding of the bladder. When a user needs to void the bladder, the user will insert the proximal insertion end 14 of the catheter product 10 through the urethra until the opening 18 for receiving urine is in the bladder. To ease with insertion of the catheter, the catheter tube may include a hydrophilic coating on an outer surface of the catheter tube. The hydrophilic coating may be transparent. Once properly inserted, urine will then flow from the bladder, through the opening 18 on the proximal insertion end 14, through the lumen, contacting the biomarker strip 22, and ultimately out of the distal drainage end 16 of the catheter product 10. The urine contacts the indicators 26 directly or indirectly. For example, urine may flow directly over the indicators 26 or the biomarker strip 22 may absorb urine as it flows over the strip, wherein the urine absorbed into the strip contacts the indicators 26. For example, referring to
In one embodiment, the indicators 26 may be color-changing sensors. When the sensor contacts the urine, the sensor may change colors to indicate the presence of a particular characteristic. The sensors may be configured to detect, for example, but not limited to, urinary tract infections, urinary tract infection causative agents, the degree of urinary tract infection, monomicrobial or polymicrobial infection status, presence of biofilm, presence of antimicrobial resistant strains, proteases, ureases, pH, dissolved nitrogen, free nitrogen, leukocyte esterase, nitrite, lipoteichoic acid, enterotoxin, endotoxin, carcinomas, membrane-bound mucins, such as MUC1 and MUC 20, and the likes.
In an exemplary embodiment, when monitoring for a urinary tract infection and/or their causative agents, the colorimetric sensor may be configured to detect for, but not limited to, the presence of biofilm, the presence of antimicrobial resistant strains, proteases, ureases, pH, dissolved nitrogen, leukocyte esterase, nitrite, lipoteichoic acid, enterotoxin, and the likes.
In another exemplary embodiment, the color-changing sensors may be an enzyme-linked immunosorbent assay (ELISA).
In another exemplary embodiment, the color-changing sensors may be configured to monitor for damage to the urethral lining by detecting MUC1, MUC20, and other mucosal glycoproteins.
In yet another exemplary embodiment, the color-changing sensors may be configured to detect biomarkers that pertain to pathological conditions, including cancerous cell development.
In yet a further embodiment, the sensors may be configured to measure specific gravity, pH, leukocytes, hemoglobin, nitrites, ketones, bilirubin, urobilinogen, proteins, glucose.
After the user has voided the bladder, the user may view the biomarker strip 22 to assess the characteristics of the urine. In an embodiment where the catheter tube 12 is made of a transparent material, the user will be able to view the biomarker strip 22 through the catheter tube 12 without having to remove the biomarker strip 22. In an embodiment where the catheter tube 12 is opaque or has an opaque coating, the user may remove the biomarker strip 22 from the catheter tube 12 to view it. The biomarker strip 22 may be removed by peeling the tab 28 off the drainage member 24 and pulling the biomarker strip 22 out. The user may use a key card indicating what a color identifies to interpret any color change on the color-changing sensors. Optionally, the user may interpret the color change on the sensors using an electronic means. For instance, but not limited to, the results of the biomarker strip 22 may be interpreted using an app. In one embodiment, the user may use a smart device (such as a cellphone or tablet) to take a photo or scan of the biomarker strip 22. The smart device may include software, an application or connection via the internet to a software that analyzes the photo/scan and provides the analysis to the user or a healthcare provider. The analysis or other data may also be stored and readably retrievable for future viewing.
In another embodiment, the indicators 26 may be sensors with wireless communication capabilities. The sensors may be configured to detect, for example, but not limited to, urinary tract infections, urinary tract infection causative agents, the degree of urinary tract infection, monomicrobial or polymicrobial infection status, presence of biofilm, presence of antimicrobial resistant strains, proteases, ureases, pH, dissolved nitrogen, free nitrogen, leukocyte esterase, nitrite, lipoteichoic acid, enterotoxin, endotoxin, carcinomas, membrane-bound mucins, such as MUC1 and MUC 20, and the likes. The sensors may communicate the presence of a detected characteristic to a computing device with a display unit, for example, but not limited to, a user's smart phone. The information may be transmitted via RFID, NFC, and/or Bluetooth technology.
A baseline level of a desired biomarker can be established and subsequently monitored at predetermined intervals through the use of a software application on the computing device. As the detected level of the biomarker changes, feedback may be sent to the user or an associated clinician. The feedback may include, for example, but not limited to, notification of an imminent or ongoing infection, the type of infection present, or other abnormalities.
It will be understood that the embodiments and examples described above are illustrative of some of the applications of the principles of the present subject matter. Numerous modifications may be made by those skilled in the art without departing from the spirit and scope of the claimed subject matter, including those combinations of features that are individually disclosed or claimed herein. For these reasons, the scope hereof is not limited to the above description but is as set forth in the following claims, and it is understood that claims may be directed to the features hereof, including as combinations of features that are individually disclosed or claimed herein.
The present application claims the benefit and priority to U.S. Provisional Patent Application No. 63/308,594, filed Feb. 10, 2022, which is hereby incorporated in its entirety herein by reference.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2023/062118 | 2/7/2023 | WO |
Number | Date | Country | |
---|---|---|---|
63308594 | Feb 2022 | US |